PainRelief.com:  What are the main findings?

Response: Results of the ADVANCE trial demonstrated that Atogepant was well tolerated. The most commonly reported treatment emergent adverse events were constipation and nausea.

PainRelief.com: What should readers take away from your report?

Response: We can conclude from the clinical trial that, at all doses – 10 mg, 30 mg and 60 mg taken orally once daily — atogepant was effective during the 12-week treatment period beginning in the first 4 weeks, as evidenced by significant reductions in mean monthly migraine days at every responder threshold level. Further, the percentage of responders at each threshold increased with duration of treatment and was sustained for 12 weeks.

Readers can take away that atogepant is effective and well tolerated for the preventive treatment of episodic migraine in adults.

PainRelief.com: What recommendations do you have for future research as a result of this work?

Response: The study results are exciting as they reinforce the efficacy of atogepant in treating adults with episodic migraine. As we further evaluate the safety and efficacy of atogepant, we look forward to evaluating real world data regarding the effectiveness of atogepant.

PainRelief.com: Is there anything else you would like to add?

Response: Atogepant is marketed as QULIPTA^TM in the United States and is FDA-approved for the preventive treatment of episodic migraine.

This study was sponsored by Allergan (prior to its acquisition by AbbVie).

Citation:

Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022;5(6):e2215499. doi:10.1001/jamanetworkopen.2022.15499

QULIPTA™ USE AND U.S. IMPORTANT SAFETY INFORMATION

QULIPTA is a prescription medicine used for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily.

Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.

OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.

Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on July 25, 2022 by PainRelief.com